FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808007788> ?p ?o ?g. }

• W2808007788 endingPage "10" @default.
• W2808007788 startingPage "10" @default.
• W2808007788 abstract "Background Randomized controlled trials of prenatal omega (ω-3) long chain polyunsaturated fatty acid (LCPUFA) supplementation are suggestive of some protective effects on allergic sensitization and symptoms of allergic disease in childhood. Due to the nature of the atopic march, investigation of any effects of this prenatal intervention may be most informative when consistently assessed longitudinally during childhood.Methods Follow-up of children (n = 706) with familial risk of allergy from the Docosahexaenoic Acid to Optimize Mother Infant Outcome (DOMInO) trial. The intervention group received fish oil capsules (900 mg of ω-3 LCPUFA) daily from <21 weeks’ gestation until birth; the control group received vegetable oil capsules without ω-3 LCPUFA. This new longitudinal analysis reports previously unpublished data collected at 1 and 3 years of age. The allergic disease symptom data at 1, 3 and 6 years of age were consistently reported by parents using the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire. Sensitization was determined by skin prick test to age specific, common allergen extracts.Results Changes over time in symptoms of allergic disease with sensitization (IgE-mediated) and sensitization did not differ between the groups; interaction p = 0.49, p = 0.10, respectively. Averaged across the 1, 3 and 6-year assessments, there were no significant effects of prenatal ω-3 LCPUFA supplementation on IgE-mediated allergic disease symptoms (adjusted relative risk 0.88 (95% CI 0.69, 1.12), p = 0.29) or sensitization (adjusted relative risk 0.97 (95% CI 0.82, 1.15), p = 0.76). Sensitization patterns to common allergens were consistent with the atopic march, with egg sensitization at 1 year strongly associated with house dust mite sensitization at 6 years, (p < 0.0001).Discussion Although there is some evidence to suggest that maternal supplementation with 900mg ω-3 LCPUFA has a protective effect on early symptoms of allergic disease and sensitization in the offspring, we did not observe any differences in the progression of disease over time in this longitudinal analysis. Further investigation into the dose and timing of ω-3 LCPUFA supplementation, including long-term follow up of children using consistent outcome reporting, is essential to determine whether this intervention may be of benefit as a primary prevention strategy for allergic disease.Conclusion Maternal supplementation with 900 mg of ω-3 LCPUFA did not change the progression of IgE-mediated allergic disease symptoms or sensitization throughout childhood from 1 to 6 years.Trial registration Australian New Zealand Clinical Trials Registry (ACTRN); DOMInO trial ACTRN12605000569606, early childhood allergy follow up ACTRN12610000735055 and 6-year allergy follow up ACTRN12615000498594." @default.
• W2808007788 created "2018-06-21" @default.
• W2808007788 creator A5031403615 @default.
• W2808007788 creator A5038952781 @default.
• W2808007788 creator A5054601886 @default.
• W2808007788 creator A5058910594 @default.
• W2808007788 creator A5073901691 @default.
• W2808007788 creator A5078043280 @default.
• W2808007788 creator A5080520984 @default.
• W2808007788 date "2018-01-01" @default.
• W2808007788 modified "2023-10-17" @default.
• W2808007788 title "Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood – a longitudinal analysis of long-term follow-up of a randomized controlled trial" @default.
• W2808007788 cites W1486774165 @default.
• W2808007788 cites W1567692140 @default.
• W2808007788 cites W1755014012 @default.
• W2808007788 cites W1972233131 @default.
• W2808007788 cites W1975121282 @default.
• W2808007788 cites W1985120441 @default.
• W2808007788 cites W1986100211 @default.
• W2808007788 cites W1994997335 @default.
• W2808007788 cites W1999100728 @default.
• W2808007788 cites W2008737029 @default.
• W2808007788 cites W2016461435 @default.
• W2808007788 cites W2018004264 @default.
• W2808007788 cites W2041749596 @default.
• W2808007788 cites W2048843416 @default.
• W2808007788 cites W2053973705 @default.
• W2808007788 cites W2057748652 @default.
• W2808007788 cites W2060727335 @default.
• W2808007788 cites W2078354342 @default.
• W2808007788 cites W2084721135 @default.
• W2808007788 cites W2089253898 @default.
• W2808007788 cites W2100259422 @default.
• W2808007788 cites W2102084287 @default.
• W2808007788 cites W2103169988 @default.
• W2808007788 cites W2104856244 @default.
• W2808007788 cites W2104967186 @default.
• W2808007788 cites W2107220802 @default.
• W2808007788 cites W2109784715 @default.
• W2808007788 cites W2111025562 @default.
• W2808007788 cites W2118278044 @default.
• W2808007788 cites W2136781140 @default.
• W2808007788 cites W2142010704 @default.
• W2808007788 cites W2213594751 @default.
• W2808007788 cites W2343043988 @default.
• W2808007788 cites W2396224155 @default.
• W2808007788 cites W2406434878 @default.
• W2808007788 cites W2566466281 @default.
• W2808007788 cites W2761361575 @default.
• W2808007788 cites W4240508402 @default.
• W2808007788 cites W64598540 @default.
• W2808007788 doi "https://doi.org/10.1186/s40413-018-0190-7" @default.
• W2808007788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6003086" @default.
• W2808007788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29977437" @default.
• W2808007788 hasPublicationYear "2018" @default.
• W2808007788 type Work @default.
• W2808007788 sameAs 2808007788 @default.
• W2808007788 citedByCount "32" @default.
• W2808007788 countsByYear W28080077882018 @default.
• W2808007788 countsByYear W28080077882019 @default.
• W2808007788 countsByYear W28080077882020 @default.
• W2808007788 countsByYear W28080077882021 @default.
• W2808007788 countsByYear W28080077882022 @default.
• W2808007788 countsByYear W28080077882023 @default.
• W2808007788 crossrefType "journal-article" @default.
• W2808007788 hasAuthorship W2808007788A5031403615 @default.
• W2808007788 hasAuthorship W2808007788A5038952781 @default.
• W2808007788 hasAuthorship W2808007788A5054601886 @default.
• W2808007788 hasAuthorship W2808007788A5058910594 @default.
• W2808007788 hasAuthorship W2808007788A5073901691 @default.
• W2808007788 hasAuthorship W2808007788A5078043280 @default.
• W2808007788 hasAuthorship W2808007788A5080520984 @default.
• W2808007788 hasBestOaLocation W28080077881 @default.
• W2808007788 hasConcept C126322002 @default.
• W2808007788 hasConcept C168563851 @default.
• W2808007788 hasConcept C187212893 @default.
• W2808007788 hasConcept C203014093 @default.
• W2808007788 hasConcept C207480886 @default.
• W2808007788 hasConcept C2776042228 @default.
• W2808007788 hasConcept C2776217527 @default.
• W2808007788 hasConcept C2779134260 @default.
• W2808007788 hasConcept C2779234561 @default.
• W2808007788 hasConcept C2779946292 @default.
• W2808007788 hasConcept C2909208804 @default.
• W2808007788 hasConcept C44249647 @default.
• W2808007788 hasConcept C46973012 @default.
• W2808007788 hasConcept C505870484 @default.
• W2808007788 hasConcept C54355233 @default.
• W2808007788 hasConcept C71924100 @default.
• W2808007788 hasConcept C82789193 @default.
• W2808007788 hasConcept C86803240 @default.
• W2808007788 hasConceptScore W2808007788C126322002 @default.
• W2808007788 hasConceptScore W2808007788C168563851 @default.
• W2808007788 hasConceptScore W2808007788C187212893 @default.
• W2808007788 hasConceptScore W2808007788C203014093 @default.
• W2808007788 hasConceptScore W2808007788C207480886 @default.
• W2808007788 hasConceptScore W2808007788C2776042228 @default.
• W2808007788 hasConceptScore W2808007788C2776217527 @default.

• next